PRESS RELEASE Biotest AG: Annual General Meeting approves dividend distribution Distribution of € 0.04 per preference share for the year 2024 Broad majority in the vote in line with the management's proposals Dreieich, 02 Juli 2025. At the Annual General Meeting on Juli 2, 2025, the shareholders of Biotest AG resolved to distribute a dividen [ … ]

  PRESS RELEASE  Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine   The data will also be presented tomorrow as part of three abstracts at the currently ongoing International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress  The Phase III AdFIrst study met its primary endpoint demonst [ … ]

  PRESS RELEASE  Biotest confirms Guidance for 2025 Sales increases for human albumin and Yimmugo First quarter in line with expectations  Dreieich, May 12, 2025. In the first quarter of fiscal year 2025, the Biotest Group generated sales of € 124.2 million. This represents a decrease of € 91.0 million or 42.3 % compared to sales of € 215.2 mi [ … ]

    PRESS RELEASE   Biotest AG increases sales by 6% in financial year 2024 EBIT guidance of € 94.5 million at the upper end of the forecast range achieved Marketing authorization application for fibrinogen submitted in key European markets and to the US Food and Drug Administration (FDA) Approval of Yimmugo in June 2024 by the US Food and D [ … ]

PRESS RELEASE   Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)   Biotest's fibrinogen aims to fulfill a high unmet medical need for additional fibrinogen to treat acquired fibrinogen deficiency US submission follows EU application for marketing authorizatio [ … ]